Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label Avastin places pressure on the U.S. branded market; however, Eylea continues to gain market share. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Dry and Wet Age-Related Macular Degeneration | Current Treatment | US detailed, expanded analysis offers a snapshot of how U.S. ophthalmologists prescribe currently available therapies as well as insight into the factors driving such prescribing habits.


Related Reports

Dry and Wet Age-Related Macular Degeneration | Landscape & Forecast | Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) market has long been dominated by three VEGF

View Details

Dry and Wet Age-Related Macular Degeneration | Special Topics | Special Topics - Beovu - Three Months Postlaunch for Wet AMD (US)

Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatme...

View Details

Dry and Wet Age-Related Macular Degeneration | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key 

View Details

Dry and Wet Age-Related Macular Degeneration | Access & Reimbursement | Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to i...

View Details